HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation

Stock News11-26

ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the translational medicine and Phase Ib clinical trial (NCT03594422) of its proprietary Class 1 new drug, olverembatinib (brand name: Narlix®), for treating gastrointestinal stromal tumors (GIST), were published in the internationally renowned journal *Signal Transduction and Targeted Therapy* (impact factor: 52.7). The study demonstrated olverembatinib's efficacy and safety in succinate dehydrogenase (SDH)-deficient GIST and, for the first time, revealed its novel anti-tumor mechanism through lipid metabolism regulation.

The Phase I trial evaluated olverembatinib's safety and anti-tumor activity in 66 patients with unresectable/metastatic GIST or other solid tumors, including 26 SDH-deficient GIST patients who had failed tyrosine kinase inhibitor (TKI) therapy. This marks the largest prospective clinical trial to date for this rare GIST subtype.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182587677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182587677","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation","media":"Stock News","content":"<p>ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the translational medicine and Phase Ib clinical trial (NCT03594422) of its proprietary Class 1 new drug, olverembatinib (brand name: Narlix®), for treating gastrointestinal stromal tumors (GIST), were published in the internationally renowned journal *Signal Transduction and Targeted Therapy* (impact factor: 52.7). The study demonstrated olverembatinib's efficacy and safety in succinate dehydrogenase (SDH)-deficient GIST and, for the first time, revealed its novel anti-tumor mechanism through lipid metabolism regulation.</p>\n<p>The Phase I trial evaluated olverembatinib's safety and anti-tumor activity in 66 patients with unresectable/metastatic GIST or other solid tumors, including 26 SDH-deficient GIST patients who had failed tyrosine kinase inhibitor (TKI) therapy. This marks the largest prospective clinical trial to date for this rare GIST subtype.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-26 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the translational medicine and Phase Ib clinical trial (NCT03594422) of its proprietary Class 1 new drug, olverembatinib (brand name: Narlix®), for treating gastrointestinal stromal tumors (GIST), were published in the internationally renowned journal *Signal Transduction and Targeted Therapy* (impact factor: 52.7). The study demonstrated olverembatinib's efficacy and safety in succinate dehydrogenase (SDH)-deficient GIST and, for the first time, revealed its novel anti-tumor mechanism through lipid metabolism regulation.</p>\n<p>The Phase I trial evaluated olverembatinib's safety and anti-tumor activity in 66 patients with unresectable/metastatic GIST or other solid tumors, including 26 SDH-deficient GIST patients who had failed tyrosine kinase inhibitor (TKI) therapy. This marks the largest prospective clinical trial to date for this rare GIST subtype.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药-B","start_time":0,"source_url":"","article_id":"1182587677","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182587677","pubTimestamp":1764126017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药-B","AAPG":"亚盛医药","BK1161":"生物科技","BK1574":"生物医药B类股","BK4139":"生物科技"},"translate_title":"港股动向|亚盛-B(06855)涨超3%研究揭示Olverembatinib通过脂质代谢调节抗肿瘤作用新机制","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1,"AAPG":1},"content_text":"ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the translational medicine and Phase Ib clinical trial (NCT03594422) of its proprietary Class 1 new drug, olverembatinib (brand name: Narlix®), for treating gastrointestinal stromal tumors (GIST), were published in the internationally renowned journal *Signal Transduction and Targeted Therapy* (impact factor: 52.7). The study demonstrated olverembatinib's efficacy and safety in succinate dehydrogenase (SDH)-deficient GIST and, for the first time, revealed its novel anti-tumor mechanism through lipid metabolism regulation.\nThe Phase I trial evaluated olverembatinib's safety and anti-tumor activity in 66 patients with unresectable/metastatic GIST or other solid tumors, including 26 SDH-deficient GIST patients who had failed tyrosine kinase inhibitor (TKI) therapy. This marks the largest prospective clinical trial to date for this rare GIST subtype.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182587677","isCrawlerRequest":true}